CIITA and neoplasm: Continuous cloning of the CIITA-transfected cells and selection of more stable and highly MHC-II-expressing transfectants can overcome the problem and result in a more efficient rejection in vivo of the modified tumor cells, as we have shown in previous analyses (57).